Jul 24

Aeterna Zentaris first quarter revenues increase to $7.

Additionally, net finance costs increased during the first one fourth of 2011 due to the change in reasonable value of the business’s warrant liability since December 31, 2010. That modification results from the periodic ‘mark-to-market’ revaluation of presently outstanding share purchase warrants.12 per simple and diluted share, compared to $5.09 per diluted and basic share, for the same period this year 2010. This increase is mainly linked to higher net finance costs and higher tax expense. Cash and cash equivalents and short-term investment totalled $41.1 million as at March 31, 2011.. Aeterna Zentaris first quarter revenues increase to $7.4 million Aeterna Zentaris Inc. Quarter 2011 Highlights Agreement signed with Yakult Honsha Co First. Ltd. for the development, commercialization and produce of perifosine, in Japan.5 million) upon achieving certain pre-founded milestones, including scientific and regulatory events in Japan, as well as double-digit royalties on future net sales of perifosine in Japan.S5 in the Supplementary Appendix). Chemokine-mediated cell migration can be important during lymphocyte development critically, immune surveillance of lymph nodes, and recruitment of immune cells to sites of inflammation. Previous experimental data suggested a job for DOCK2 in actin polymerization and chemotactic responses of T lymphocytes and B lymphocytes after chemokine stimulation.9,10 Indeed, the chemotactic response of T cells and B cells acquired from Patients 1 and 2 was profoundly impaired .